With sticky inflation and higher-for-longer rates, sector rotation favors cash flows over short-term bounces. SCHD’s gap-fill seems fragile without broader risk-on.
Basically, SCHD is down and someone’s saying they’ll buy the dip at 33.75. The idea is that a gap close would confirm strength, but it could also just be noise. Feels risky without volume confirmation.
Another pump-and-dump setup disguised as opportunity.
Volatility like this is where I nibble. If SMCI keeps compounding, I’ll scale in slowly, pairing it with a small NVDA position to balance risk. Not chasing, just riding the momentum.
Kinda torn here—love the growth story, but the cap/earnings gap makes me uneasy. Anyone else feel whiplash watching it?
SMCI looks cheap, but growth feels unsustainable.
I’ve held GLW since 2022; fiber demand is real, but I’m trimming into strength and rotating some into MSFT.
For someone just starting, is GLW better than specialty ETFs like SOFI here, or does it lag on cycles?
Seen this movie—material winners lag demand cycles.
If MRNA’s targets keep climbing, what’s the real driver? Regulatory hurdles, production costs, or just optimism? How much of this is based on 2027/2028 demand, which feels speculative?
MRNA target rose from $33 to $95 in six months.
I’m new here—does an equal weight target mean MS thinks MRNA is fairly valued, or just not a top pick?
